Filtered By:
Drug: Rituxan

This page shows you your search results in order of date. This is page number 14.

Order by Relevance | Date

Total 306 results found since Jan 2013.

Rituximab desensitization in three patients with severe rituximab allergy
Rituximab is a chimeric monoclonal antibody that targets CD20 positive B cells and has a positive effect on both overall and progression-free survival in B cell lymphoid malignancies. Combination rituximab with chemotherapy treatment provide survival improvement. Although rituximab is an important treatment option in hematological malignancies, the risk of allergic reactions is high. These reactions are usually IgE-mediated and can be varied in regards of severity from urticaria to anaphylaxis. It is an option to interrupt the treatment and ommit rituximab therapy who had allergic reactions.
Source: Current Problems in Cancer - July 28, 2017 Category: Cancer & Oncology Authors: Erman Öztürk, Leyla Pur Özyiğit, Ayşe Bilge Öztürk, Meltem Olga Akay, Mustafa Çetiner, Burhan Ferhanoğlu Source Type: research

Erratum
In the article entitled “Modern challenges of allergic bronchopulmonary aspergillosis diagnosis and management: Finding from a case study with a history of rituximab use” (Ann Allergy Asthma Immunol 2017;119:83-97), the authors' names appear incorrectly. The authors' correct names are as follows:
Source: Annals of Allergy, Asthma and Immunology - July 28, 2017 Category: Allergy & Immunology Tags: Erratum Source Type: research

Real-world clinical experience of biological disease modifying anti-rheumatic drugs in Malaysia rheumatoid arthritis patients
AbstractThe effect of biologic disease modifying anti-rheumatic drugs (bDMARDs) in treating rheumatoid arthritis (RA) in real-world clinical practice remains unknown in Southeast Asia. We aimed to assess the efficacy and safety of bDMARDs among Malaysian RA patients treated in routine clinical practice. A retrospective medical chart review of RA patients from 11 government hospitals were conducted from January 2003 to January 2014. A standardized questionnaire was used to abstract patient ’s demographic, clinical and treatment data. Level of disease activity was measured by DAS28 collected at baseline, 3, 6 and 12 month...
Source: Rheumatology International - July 10, 2017 Category: Rheumatology Source Type: research

Modern challenges of allergic bronchopulmonary aspergillosis diagnosis and management: Finding from a case study with a history of rituximab use.
PMID: 28668248 [PubMed - in process]
Source: Annals of Allergy, Asthma and Immunology - July 1, 2017 Category: Allergy & Immunology Authors: García-Granero DB, Vera DG, Grande C, Jimenez RB, Rodriguez CF, Bobolea I Tags: Ann Allergy Asthma Immunol Source Type: research

Alternative treatments for chronic spontaneous urticaria beyond the guideline algorithm
Purpose of review: The international EAACI/GA2LEN/EDF/WAO guideline suggests a stepwise approach for the therapeutic management of chronic spontaneous urticaria (CSU), outlined in an algorithm. The aim of this article is to summarize and review the evidence available on alternative treatment options for CSU outside of this algorithm. Recent findings: Although CSU is a common disease, there are a limited number of high-quality studies, and only antihistamines and omalizumab are licensed for its treatment. Most studies regarding alternative therapies for CSU show methodological limitations and a high risk of bias. For many ...
Source: Current Opinion in Allergy and Clinical Immunology - June 29, 2017 Category: Allergy & Immunology Tags: SKIN ALLERGY: Edited by Thomas Werfel and Torsten Zuberbier Source Type: research

Lymphocytes as Biomarkers of Therapeutic Response in Rheumatic Autoimmune Diseases, Is It a Realistic Goal?
AbstractMany therapies are available for patients with rheumatoid arthritis (RA) while biological therapies have limited effects in patients with systemic lupus erythematosus (SLE) and primary Sj ögren’s syndrome (pSS). In both cases, biomarkers predicting drug response would be very useful to guide clinicians in their choice. We performed a systematic review to evaluate the value of lymphocyte phenotyping as a marker of therapeutic response. Of the 1063 articles retrieved, 39 fulfilled i nclusion criteria and were included in the present review (25 for RA, 10 for SLE, and 4 for pSS). Lymphocyte phenotyping was describe...
Source: Clinical Reviews in Allergy and Immunology - May 30, 2017 Category: Allergy & Immunology Source Type: research

Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis
Conclusions The malignancy risk in patients with AAV was lower in rituximab-treated patients than in cyclophosphamide-treated patients. Notably, rituximab treatment was not associated with an increased malignancy risk compared with the general population. Rituximab could therefore be a safe alternative to cyclophosphamide in the treatment of AAV.
Source: Annals of the Rheumatic Diseases - May 13, 2017 Category: Rheumatology Authors: van Daalen, E. E., Rizzo, R., Kronbichler, A., Wolterbeek, R., Bruijn, J. A., Jayne, D. R., Bajema, I. M., Rahmattulla, C. Tags: Immunology (including allergy), Drugs: musculoskeletal and joint diseases, Vascularitis Clinical and epidemiological research Source Type: research

Rituximab in the Treatment of Inflammatory Myopathies Rituximab in the Treatment of Inflammatory Myopathies
Get up-to-date on what there is to know about the use of rituximab therapy in the management of myositis.Rheumatology
Source: Medscape Allergy Headlines - March 2, 2017 Category: Allergy & Immunology Tags: Rheumatology Journal Article Source Type: news

Response to: Cryoglobulinemic vasculitis in the era of direct-acting antiviral drug
We thank Moiseev et al for their interest in our work regarding sofosbuvir and ribavirin in hepatitis C virus (HCV)-associated mixed cryoglobulinemia vasculitis (VASCUVALDIC study)1 and to bring new elements for discussion. Moiseev et al emphasise that treatment with immunomodulatory or immunosuppressive therapy (including rituximab) may have contributed to the impressive results of the VASCUVALDIC study. We have to stress that with the advent of new direct-acting antiviral (DAA) drugs (ie, sofosbuvir plus ribavirin), up to 87.5% of patients achieved complete clinical remission while only 17% of patients required the use o...
Source: Annals of the Rheumatic Diseases - February 16, 2017 Category: Rheumatology Authors: Saadoun, D., Cacoub, P. Tags: Immunology (including allergy), Renal medicine, Degenerative joint disease, Musculoskeletal syndromes, Vascularitis Correspondence response Source Type: research

Application of autologous hematopoietic stem cell transplantation for pemphigus
ConclusionOverall APHSCT is a promising therapeutic option for pemphigus.
Source: International Journal of Dermatology - January 17, 2017 Category: Dermatology Authors: Menglei Wang, Can Cao, Jing Sun, Xuebiao Peng, Qifa Liu, Liang Huang, Yanyan Chai, Kuan Lai, Pingjiao Chen, Qingxiu Liu, Qian Li, Yusheng Peng, Hao Xiong, Jing Zhang, Minghua Chen, Kang Zeng Tags: Report Source Type: research

Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers
Conclusions This large European collaborative project did not confirm an overall increased risk of melanoma following exposure to TNFi.
Source: Annals of the Rheumatic Diseases - January 9, 2017 Category: Rheumatology Authors: Mercer, L. K., Askling, J., Raaschou, P., Dixon, W. G., Dreyer, L., Hetland, M. L., Strangfeld, A., Zink, A., Mariette, X., Finckh, A., Canhao, H., Iannone, F., Zavada, J., Morel, J., Gottenberg, J.-E., Hyrich, K. L., Listing, J. Tags: Open access, Immunology (including allergy), Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis Clinical and epidemiological research Source Type: research

Looking forward to new targeted treatments for chronic spontaneous urticaria
AbstractThe introduction of omalizumab to the management of chronic spontaneous urticaria (CSU) has markedly improved the therapeutic possibilities for both, patients and physicians dealing with this disabling disease. But there is still a hard core of patients who do not tolerate or benefit from existing therapies and who require effective treatment. Novel approaches include the use of currently available drugs off-licence, investigational drugs currently undergoing clinical trials and exploring the potential for therapies directed at pathophysiological targets in CSU. Off-licence uses of currently available drugs include...
Source: Clinical and Translational Allergy - January 9, 2017 Category: Allergy & Immunology Source Type: research

Rapid Drug Desensitization with Biologics: A Single-Center Experience with Four Biologics
Conclusion: RDD was found to be safe and effective in the largest case series of RDDs with biologics in our country, Turkey.Int Arch Allergy Immunol 2016;171:227-233
Source: International Archives of Allergy and Immunology - January 4, 2017 Category: Allergy & Immunology Source Type: research

Ofatumumab in two pediatric nephrotic syndrome patients allergic to rituximab
ConclusionsOfatumumab may be a therapeutic option in severe forms of NS with allergy to rituximab.
Source: Pediatric Nephrology - November 26, 2016 Category: Urology & Nephrology Source Type: research

Rituximab use in a patient with anti-ri positive opsoclonus myoclonus syndrome
We describe a patient with OMS, who had a previous (and completely treated) diagnosis of Breast cancer more than 10 years ago, who presented with features of dizziness, opsoclonus, generalised myoclonus and truncal ataxia. Investigations revealed positive anti-Ri antibodies, but comprehensive screen for an underlying malignancy was negative. Patient was initially treated with intravenous immunoglobulins (IVIg) with good response. However, despite this patient had a further relapse which required hospitalisation with ventilator support and another course of IVIg. A second relapse was treated with pulsed IV cyclophosphamide ...
Source: Journal of Neurology, Neurosurgery and Psychiatry - November 14, 2016 Category: Neurosurgery Authors: Sadalage, G., Bowen, J., Nightingale, S., Jacob, S. Tags: Immunology (including allergy), Cranial nerves, Drugs: CNS (not psychiatric), Ophthalmology, Adult intensive care, Drugs: musculoskeletal and joint diseases ABN Annual Meeting, 17-19 May 2016, The Brighton Centre, Brighton Source Type: research